keyword
MENU ▼
Read by QxMD icon Read
search

Plaque psoriasis

keyword
https://www.readbyqxmd.com/read/28929168/long-term-impact-of-ixekizumab-on-psoriasis-itch-severity-results-from-a-phase-iii-clinical-trial-and-long-term-extension
#1
Alexandra B Kimball, Thomas Luger, Alice Gottlieb, Luis Puig, Roland Kaufmann, Russel Burge, Chen-Yen Lin, Gil Yosipovitch
Itching is a prevalent plaque psoriasis symptom. Ixekizumab, an IL-17A antagonist, has demonstrated rapid, significant improvements in itch severity over 12 weeks in Phase III psoriasis trials (UNCOVER-1, UNCOVER-2). We assessed the long-term (through 60 weeks) effect of ixekizumab maintenance therapy (80-mg ixekizumab every 4 weeks [IXEQ4W]) on itch severity, using the Itch Numeric Rating Scale, in psoriasis patients who received ixekizumab, placebo, or etanercept for 12 weeks in the Phase III UNCOVER-3 trial...
September 20, 2017: Acta Dermato-venereologica
https://www.readbyqxmd.com/read/28921458/pharmacogenetics-and-pharmacogenomics-in-moderate-to-severe-psoriasis
#2
REVIEW
María C Ovejero-Benito, Ester Muñoz-Aceituno, Alejandra Reolid, Miriam Saiz-Rodríguez, Francisco Abad-Santos, Esteban Daudén
Pharmacogenetics is the study of variations in DNA sequence related to drug response. Moreover, the evolution of biotechnology and the sequencing of human DNA have allowed the creation of pharmacogenomics, a branch of genetics that analyzes human genes, the RNAs and proteins encoded by them, and the inter-and intra-individual variations in expression and function in relation to drug response. Pharmacogenetics and pharmacogenomics are being used to search for biomarkers that can predict response to systemic treatments, including those for moderate-to-severe psoriasis...
September 18, 2017: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/28917574/-apparent-worsening-of-psoriasis-lesions-revealing-methotrexate-overdosage
#3
R Haber, B Baroudjian, M Battistella, M Bagot, A Petit
BACKGROUND: Methotrexate (MTX) is an antimetabolite drug used in the treatment of cancers and autoimmune diseases and frequently in dermatology for cutaneous and/or arthritic psoriasis. Toxicities due to MTX overdosage are mainly cutaneous, hepatic and hematologic. Herein, we report a case of MTX overdosage presenting as an erosive and an inflammatory flare of preexisting psoriatic plaques and with new palmar lesions. PATIENTS AND METHODS: A 51-year-old male with a 6-year history of plaque psoriasis resistant to topical corticosteroids was started for the first time on MTX 20mg weekly...
September 13, 2017: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/28917454/a-phase-2a-open-label-pilot-study-of-the-galectin-3-inhibitor-gr-md-02-for-the-treatment-of-moderate-to-severe-plaque-psoriasis
#4
Simon Ritchie, Danielle Neal, Harold Shlevin, Adam Allgood, Peter Traber
No abstract text is available yet for this article.
October 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28917383/efficacy-and-safety-of-ixekizumab-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-results-through-108%C3%A2-weeks-of-a-randomized-controlled-phase-3-clinical-trial-uncover-3
#5
Andrew Blauvelt, Melinda Gooderham, Lars Iversen, Susan Ball, Lu Zhang, Noah O Agada, Kristian Reich
BACKGROUND: Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin 17A, is efficacious in treating moderate-to-severe plaque psoriasis through 60 weeks. OBJECTIVE: To evaluate the efficacy and safety of ixekizumab through 108 weeks of treatment in UNCOVER-3. METHODS: Patients (N = 1346) were randomized 2:2:2:1 to 80 mg ixekizumab every 2 or 4 weeks, 50 mg etanercept twice weekly, or placebo. At week 12, patients switched to ixekizumab every 4 weeks during a long-term extension (LTE) period...
September 13, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28906051/effectiveness-and-safety-of-secukinumab-in-69-patients-with-moderate-to-severe-plaque-psoriasis-a-retrospective-multicenter-study
#6
J F Schwensen, A Clemmensen, C Sand, R Gniadecki, L Skov, C Zachariae, L Iversen, M Rasmussen, S F Thomsen
Secukinumab (anti-IL17A) is effective as treatment for moderate to severe plaque psoriasis, but real-life data on effectiveness and safety lack. We aimed to present real-life data of all Danish patients treated with secukinumab (n = 69). At baseline, before initiation of treatment with secukinumab 300 mg (47.8%) or off-label treatment with secukinumab 150 mg (52.2%), the median PASI score was 7.1. A total of 66.7% (34/51) and 52.9% (27/51) of patients still on secukinumab at week 12 achieved a PASI (Psoriasis Area and Severity Index)-50 and PASI-75 of 66...
September 14, 2017: Dermatologic Therapy
https://www.readbyqxmd.com/read/28903122/impact-of-ixekizumab-treatment-on-depressive-symptoms-and-systemic-inflammation-in-patients-with-moderate-to-severe-psoriasis-an-integrated-analysis-of-three-phase-3-clinical-studies
#7
Christopher E M Griffiths, Maurizio Fava, Andrew H Miller, James Russell, Susan G Ball, Wen Xu, Nayan Acharya, Mark Hyman Rapaport
BACKGROUND: Depression is a common comorbidity in psoriasis, and both conditions are associated with systemic inflammation. The efficacy of ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A, was evaluated in patients with moderate-to-severe plaque psoriasis (psoriasis) and depressive symptoms that were at least moderately severe. METHODS: Data were integrated from 3 randomized, double-blind, controlled phase 3 trials. At baseline and week 12, depressive symptoms and inflammation were assessed by the 16-item Quick Inventory of Depressive Symptomology - Self-Report (QIDS-SR16) and by a high-sensitivity assay of serum C-reactive protein (hsCRP), respectively...
September 14, 2017: Psychotherapy and Psychosomatics
https://www.readbyqxmd.com/read/28894050/compounds-of-psoriasis-with-obesity-and-overweight
#8
Agnieszka Owczarczyk-Saczonek, Waldemar Placek
Many epidemiological studies have confirmed the relationship of obesity and psoriasis, and it is believed that obesity is an independent risk factor for its development and is associated with a worse prognosis. Furthermore, the reduction of body weight, using low-calorie diet combined with exercise, reduces the severity of psoriasis.Visceral adipose tissue is the largest endocrine organ, producing proinflammatory cytokines (TNF-α, IL-6, IL-17) and adipokines (adiponectin, omentin, chemerin). They participate in the development of dyslipidemia, insulin resistance, diabetes, and consequently of the cardiovascular diseases...
August 24, 2017: Postȩpy Higieny i Medycyny Doświadczalnej
https://www.readbyqxmd.com/read/28893023/itolizumab-in-the-management-of-psoriasis-with-metabolic-syndrome
#9
Shrichand G Parasramani
Psoriasis is a chronic, relapsing, inflammatory disease that has been associated with Metabolic Syndrome (MS), a cluster of cardiovascular risk factors mainly hypertension, obesity, diabetes mellitus and hyperlipidemia. A 49-year-old male patient presented with extensive plaque psoriasis from past 13 years. Past medications included methotrexate, PUVA therapy, topical immunosuppressants and corticosteroids. His baseline Psoriasis Area and Severity Index (PASI) score was 39.8. The patient was screened and diagnosed with MS as per Alberti's Criteria (his waist circumference was 100 cm, blood pressure was 160/100 mmHg and High Density Lipoprotein (HDL) was 30 mg/dl)...
July 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28892900/immunohistochemical-expression-of-caspase-3-in-psoriasis
#10
Shaimaa M M Bebars, Dalia Rifaat Al-Sharaky, Mohammed A Gaber, Dina Ragab Afify
INTRODUCTION: Psoriasis is a persistent chronic immune-mediated, relapsing, inflammatory and hyper proliferative skin disorder with genetic predisposition. Psoriasis can be considered as a T-cell mediated disease, with a complex role for a variety of cytokine interaction between keratinocytes and T-lymphocytes. Caspase-3 is an enzyme that plays a key role in apoptosis; it is a member of the family of cysteinyle aspartate specific proteases. AIM: To evaluate the expression of caspase-3 in Egyptian psoriasis patients and its role in apoptosis of keratinocytes...
July 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28887948/psoriasis-pathogenesis-and-the-development-of-novel-targeted-immune-therapies
#11
REVIEW
Jason E Hawkes, Tom C Chan, James G Krueger
Psoriasis is caused by a complex interplay between the immune system, psoriasis-associated susceptibility loci, autoantigens, and multiple environmental factors. Over the last 2 decades, research has unequivocally shown that psoriasis represents a bona fide T cell-mediated disease primarily driven by pathogenic T cells that produce high levels of IL-17 in response to IL-23. The discovery of the central role for the IL-23/type 17 T-cell axis in the development of psoriasis has led to a major paradigm shift in the pathogenic model for this condition...
September 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28879789/a-review-article-on-brodalumab-in-the-treatment-of-moderate-to-severe-plaque-psoriasis
#12
Omid Roostaeyan, Dario Kivelevitch, Alan Menter
Psoriasis is a chronic immune-mediated skin disorder affecting approximately 2-3% of the worldwide population. Recent advances in our understanding of the immunopathogenesis of psoriasis have resulted in novel therapeutic agents. IL-17, a pro-inflammatory cytokine, plays a pivotal role in psoriasis. Therapeutic agents targeting this cytokine have shown clinical effectiveness in the treatment of moderate-to-severe plaque psoriasis. Brodalumab, a human antibody against IL-17 receptor A, has been approved by the US FDA in February 2017, by the Japanese Pharmaceuticals and Medical Devices Agency in July 2016 and by the EMA in July 2017 for the treatment of moderate-to-severe psoriasis...
September 7, 2017: Immunotherapy
https://www.readbyqxmd.com/read/28879648/is-there-any-difference-in-acromegaly-and-other-chronic-disease-in-quality-of-life-and-psychiatric-morbidity
#13
Dorota Maria Szcześniak, Aleksandra Jawiarczyk-Przybyłowska, Łukasz Matusiak, Anna Bolanowska, Julian Maciaszek, Małgorzata Siemińska, Joanna Rymaszewska, Marek Bolanowski
INTRODUCTION: The study aimed to evaluate the psychological profile of patients with acromegaly in comparison to other chronic diseases such as non-functioning pituitary adenomas, Cushing disease, plaque psoriasis, and to the healthy control group. MATERIALS AND METHODS: A total sample of 153 participants in clinical groups underwent a cross-sectional assessment including the quality of life (AcroQoL, WHOQoL-BREF), psychiatric morbidity (GHQ-28) and the acceptance of illness (AIS) and 65 participants in the healthy control group...
September 7, 2017: Endokrynologia Polska
https://www.readbyqxmd.com/read/28871932/a-12-year-old-girl-with-severe-plaque-psoriasis-and-down-syndrome-treated-successfully-with-etanercept
#14
Michał Adamczyk, Małgorzata Michalska-Jakubus, Dorota Krasowska
The association between Down syndrome and psoriasis is unclear. Immunological abnormalities that present in individuals with Down syndrome result in mild immune debilitation, thus the risk of infectious complications during immunosuppressive therapy might be higher in this group of patients. We present a case of 12-year-old girl with severe plaque psoriasis and Down syndrome, who was initially treated with cyclosporine with good response. However, the drug was withdrawn due to massive viral warts development and loss of efficacy...
July 2017: Acta Dermatovenerologica Croatica: ADC
https://www.readbyqxmd.com/read/28868144/inhibition-of-il-17a-by-secukinumab-shows-no-evidence-of-increased-mycobacterium-tuberculosis-infections
#15
Michael Kammüller, Tsen-Fang Tsai, Christopher Em Griffiths, Nidhi Kapoor, Pappachan E Kolattukudy, Dominique Brees, Salah-Dine Chibout, Jorge Safi, Todd Fox
Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin-17A (IL-17A), has been shown to have significant efficacy in the treatment of moderate to severe psoriasis, psoriatic arthritis and ankylosing spondylitis. Blocking critical mediators of immunity may carry a risk of increased opportunistic infections. Here we present clinical and in vitro findings examining the effect of secukinumab on Mycobacterium tuberculosis infection. We re-assessed the effect of secukinumab on the incidence of acute tuberculosis (TB) and reactivation of latent TB infection (LTBI) in pooled safety data from five randomized, double-blind, placebo-controlled, phase 3 clinical trials in subjects with moderate to severe plaque psoriasis...
August 2017: Clinical & Translational Immunology
https://www.readbyqxmd.com/read/28865459/clinical-efficacy-and-il-17-targeting-mechanism-of-indigo-naturalis-as-a-topical-agent-in-moderate-psoriasis
#16
RANDOMIZED CONTROLLED TRIAL
Hui-Man Cheng, Yang-Chang Wu, Qingmin Wang, Michael Song, Jackson Wu, Dion Chen, Katherine Li, Eric Wadman, Shung-Te Kao, Tsai-Chung Li, Francisco Leon, Karen Hayden, Carrie Brodmerkel, C Chris Huang
BACKGROUND: Indigo naturalis is a Traditional Chinese Medicine (TCM) ingredient long-recognized as a therapy for several inflammatory conditions, including psoriasis. However, its mechanism is unknown due to lack of knowledge about the responsible chemical entity. We took a different approach to this challenge by investigating the molecular profile of Indigo naturalis treatment and impacted pathways. METHODS: A randomized, double-blind, placebo-controlled clinical study was conducted using Indigo naturalis as topical monotherapy to treat moderate plaque psoriasis in a Chinese cohort (n = 24)...
September 2, 2017: BMC Complementary and Alternative Medicine
https://www.readbyqxmd.com/read/28859739/brodalumab-siliq-%C3%A2-a-treatment-for-plaque-psoriasis
#17
Aditya K Gupta, Sarah Versteeg Versteeg, William Abramovits, Kimberly D Vincent
No abstract text is available yet for this article.
2017: Skinmed
https://www.readbyqxmd.com/read/28836690/methotrexate-but-not-narrowband-ultraviolet-b-radiation-suppresses-interleukin-33-mrna-levels-in-psoriatic-plaques-and-protein-levels-in-serum-of-patients-with-psoriasis
#18
Jitlada Meephansan, Urairack Subpayasarn, Saranyoo Ponnikorn, Panlop Chakkavittumrong, Premjit Juntongjin, Mayumi Komine, Mamitaro Ohtsuki, Yong Poovorawan
Interleukin (IL)-33 can function both as a conventional cytokine and as a nuclear factor regulating gene transcription. IL-33 expression is strongly upregulated in the nucleus of keratinocytes and serum of patients with psoriasis. However, the role of IL-33 in psoriasis is unclear, and IL-33 expression in the lesional psoriatic skin after conventional systemic treatments has not been investigated. In this study, we aimed to compare IL-33 mRNA in patients' lesional skin samples and IL-33 protein expression in patients' serum before and after treatment with methotrexate (MTX) and narrowband ultraviolet B (NB-UVB)...
August 24, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/28836064/treatment-of-severe-psoriasis-in-children-recommendations-of-an-italian-expert-group
#19
Anna Belloni Fortina, Federico Bardazzi, Samantha Berti, Claudia Carnevale, Vito Di Lernia, Maya El Hachem, Iria Neri, Carlo Mario Gelmetti, Viviana Lora, Carlo Mazzatenta, Mirella Milioto, Gaia Moretta, Annalisa Patrizi, Ketty Peris, Alberto Villani
This article provides comprehensive recommendations for the systemic treatment of severe pediatric psoriasis based on evidence obtained from a systematic review of the literature and the consensus opinion of expert dermatologists and pediatricians. For each systemic treatment, the grade of recommendation (A, B, C) based on the treatment's approval by the European Medicines Agency for childhood psoriasis and the experts' opinions is discussed. The grade of recommendation for narrow-band-ultraviolet B phototherapy, cyclosporine, and retinoids is C, while that for methotrexate is C/B...
August 23, 2017: European Journal of Pediatrics
https://www.readbyqxmd.com/read/28833973/successful-ustekinumab-treatment-of-noninfectious-uveitis-and-concomitant-severe-psoriatic-arthritis-and-plaque-psoriasis
#20
Cristina Mugheddu, Laura Atzori, Maria Del Piano, Astrid Lappi, Monica Pau, Severino Murgia, Ignazio Zucca, Franco Rongioletti
We report the first successful treatment of noninfectious uveitis with ustekinumab in a patient with severe concomitant psoriasis and psoriatic arthritis who failed to respond to conventional immune suppressants and with contraindications to tumor necrosis factor alpha inhibitors.
August 18, 2017: Dermatologic Therapy
keyword
keyword
82378
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"